首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Quinolone Resistance Mutations in Streptococcus pneumoniae GyrA and ParC Proteins: Mechanistic Insights into Quinolone Action from Enzymatic Analysis Intracellular Levels and Phenotypes of Wild-Type and Mutant Proteins
【2h】

Quinolone Resistance Mutations in Streptococcus pneumoniae GyrA and ParC Proteins: Mechanistic Insights into Quinolone Action from Enzymatic Analysis Intracellular Levels and Phenotypes of Wild-Type and Mutant Proteins

机译:肺炎链球菌GyrA和ParC蛋白中的喹诺酮抗药性突变:从酶学分析细胞内水平以及野生型和突变体蛋白的表型对喹诺酮作用的机理研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mutations in DNA gyrase and/or topoisomerase IV genes are frequently encountered in quinolone-resistant mutants of Streptococcus pneumoniae. To investigate the mechanism of their effects at the molecular and cellular levels, we have used an Escherichia coli system to overexpress S. pneumoniae gyrase gyrA and topoisomerase IV parC genes encoding respective Ser81Phe and Ser79Phe mutations, two changes widely associated with quinolone resistance. Nickel chelate chromatography yielded highly purified mutant His-tagged proteins that, in the presence of the corresponding GyrB and ParE subunits, reconstituted gyrase and topoisomerase IV complexes with wild-type specific activities. In enzyme inhibition or DNA cleavage assays, these mutant enzyme complexes were at least 8- to 16-fold less responsive to both sparfloxacin and ciprofloxacin. The ciprofloxacin-resistant (Cipr) phenotype was silent in a sparfloxacin-resistant (Spxr) S. pneumoniae gyrA (Ser81Phe) strain expressing a demonstrably wild-type topoisomerase IV, whereas Spxr was silent in a Cipr parC (Ser79Phe) strain. These epistatic effects provide strong support for a model in which quinolones kill S. pneumoniae by acting not as enzyme inhibitors but as cellular poisons, with sparfloxacin killing preferentially through gyrase and ciprofloxacin through topoisomerase IV. By immunoblotting using subunit-specific antisera, intracellular GyrA/GyrB levels were a modest threefold higher than those of ParC/ParE, most likely insufficient to allow selective drug action by counterbalancing the 20- to 40-fold preference for cleavable-complex formation through topoisomerase IV observed in vitro. To reconcile these results, we suggest that drug-dependent differences in the efficiency by which ternary complexes are formed, processed, or repaired in S. pneumoniae may be key factors determining the killing pathway.
机译:DNA促旋酶和/或拓扑异构酶IV基因的突变在肺炎链球菌对喹诺酮耐药的突变体中经常遇到。为了研究它们在分子和细胞水平上的作用机理,我们使用了大肠杆菌系统过表达肺炎链球菌回旋酶gyrA和拓扑异构酶IV parC基因,分别编码Ser81Phe和Ser79Phe突变,这两个变化与喹诺酮耐药性广泛相关。镍螯合物色谱法产生高度纯化的突变His-tagged蛋白,在相应的GyrB和ParE亚基存在下,可重构具有野生型比活性的回旋酶和拓扑异构酶IV复合物。在酶抑制或DNA裂解测定中,这些突变型酶复合物对司帕沙星和环丙沙星的反应至少低8至16倍。耐环丙沙星的(Cip r )表型在表达耐野生型拓扑异构酶IV的耐司帕沙星(spx r )的肺炎链球菌gyrA(Ser81Phe)菌株中沉默。 ,而Spx r 在Cip r parC(Ser79Phe)株中沉默。这些上位性作用为喹诺酮类药物不通过酶抑制剂而是细胞毒物杀死肺炎链球菌的模型提供了有力的支持,而司帕沙星则优先通过促旋酶和环丙沙星通过拓扑异构酶IV来杀灭。通过使用亚基特异性抗血清进行免疫印迹,细胞内GyrA / GyrB水平比ParC / ParE适度高三倍,很可能不足以通过平衡拓扑异构酶平衡20到40倍可裂解复合物的形成来实现选择性药物作用体外观察IV。为了使这些结果一致,我们建议在肺炎链球菌中形成,加工或修复三元复合物的效率的药物依赖性差异可能是决定杀伤途径的关键因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号